TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Aldevron and Acuitas Therapeutics Establish Strategic Partnership

Tuesday, May 14, 2024

Aldevron, a global leader in manufacturing DNA, RNA, and proteins crucial for cell and gene therapies and vaccine development, has announced a strategic partnership with Acuitas Therapeutics, Inc., a biotech company specializing in nucleic acid therapeutics delivery systems using lipid nanoparticles (LNPs). This collaboration aims to enhance Aldevron's capabilities in mRNA LNP encapsulation by incorporating Acuitas’ proprietary LNP encapsulation platform, expanding Aldevron’s services and capabilities as an mRNA custom manufacturer from sequence to vial.

In May 2023, Aldevron expanded its mRNA production capabilities to include Cytiva’s mRNA LNP encapsulation and aseptic fill-finish platform. This new partnership with Acuitas Therapeutics complements Aldevron’s existing capabilities, offering a range of mRNA LNP technologies. This collaboration enables Aldevron to support Acuitas’ LNP formulations and licensees.

Aldevron, expressed excitement about the collaboration, stating, “This collaboration with Acuitas is a significant addition to our mRNA sequence-to-vial services, allowing Acuitas partners to benefit from our extensive mRNA manufacturing experience and comprehensive capabilities.”

Acuitas Therapeutics, Inc., emphasized the potential of the partnership to expedite the delivery of new mRNA-based therapies globally. He stated, “We are pleased to work with Aldevron to provide Acuitas partners with an integrated path to clinical drug products using Acuitas’ lipid nanoparticle manufacturing processes.”

Wetzel highlighted the advantage of combining Acuitas’ technology with Aldevron’s expertise, stating, “The Acuitas technology, combined with Aldevron’s extensive experience in advancing therapies and rigorous quality processes, provides an exceptional advantage.” This partnership promises clients flexibility in LNP platforms tailored to their program’s developmental stage, leveraging Aldevron’s two decades of mRNA technology experience and streamlined workflow from mRNA sequence to vial.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit